The company’s statement comes amid speculations that the US drug giant may sell its vaccines in open market now that the govt has allowed vaccine-makers the choice of setting their own prices for states and personal hospitals.
“For India, Pfizer has offered a not-for-profit price for its vaccine for the govt immunization program. We still be in discussions with the govt and remain committed to form our vaccine available for deployment in India’s immunization program,” a Pfizer spokesperson stated.
While Pfizer was the primary company to hunt emergency approval in India for its vaccine with BioNTech, its application was rejected because it had not conducted local trials of the vaccine here. However, amid a surge in cases, the govt reversed its earlier policy on foreign vaccines that had not been tested in India.
This was partially thanks to a shortage of vaccines and a slow ramp-up in production of existing Covid-19 vaccines within the country.
